YH001

YH001 monoclonal antibody targeting CTLA-4 can enhance the removal of regulatory T cells (Treg cells) in the tumor microenvironment by improving the immune response against tumor cells in order to treat multiple tumors. Enhancing patients' immune responses to tumors by blocking inhibitory signals of...

YH002

Preclinical data of YH002 monoclonal antibody targeting OX40 agonists demonstrated that YH002 could compete with OX40L in binding to OX40, activate OX40/OX40L and a series of signaling pathways to greatly promote T cell activation and proliferation. YH002 had excellent immune activation and good saf...

YH003

YH003 is a humanized agonistic antibody that promotes CD40 activation on antigen-presenting cells by specifically binding to the CD40 receptor to positively regulate the effector activity of anti-tumor T cells. Studies to date demonstrated that activation of CD40 is a key regulator of tumor immunoth...